Efruxifermin induces NASH resolution, improves fibrosis by at least 1 stage vs. placebo

WASHINGTON — Efruxifermin improved liver histology, liver fat content and noninvasive markers of disease in patients with stage 2 or 3 fibrosis related to nonalcoholic steatohepatitis, according to late-breaking data at The Liver Meeting.In a previous phase 2a study, efruxifermin (EFX), a long-acting FGF21 analog, reduced liver fat content in patients with stage F1 to…

VIDEO: Livmarli reduces pruritus in progressive familial intrahepatic cholestasis subtypes

WASHINGTON — In a Healio video exclusive, Alexander G. Miethke, MD, noted that Livmarli demonstrated significant reductions in pruritus and serum bile acids across multiple subtypes of progressive familial intrahepatic cholestasis.Topline results from the phase 3 MARCH study were presented during a late-breaking oral abstract session at The Liver Meeting.In their study, Miethke, associate professor…

‘Significant’ racial, ethnic disparities exist in curative treatment for early-stage HCC

WASHINGTON — Fewer Black and Hispanic patients received curative treatment for early-stage hepatocellular carcinoma compared with white patients, according to research presented at The Liver Meeting.“HCC is the third leading cause of cancer-related death worldwide. Prognosis varies significantly based on stage of diagnosis. Unfortunately, HCC is usually detected at a later stage when treatment options…

VIDEO: Livmarli reduces pruritus in progressive familial intrahepatic cholestasis subtypes

WASHINGTON — In a Healio video exclusive, Alexander G. Miethke, MD, noted that Livmarli demonstrated significant reductions in pruritus and serum bile acids across multiple subtypes of progressive familial intrahepatic cholestasis.Topline results from the phase 3 MARCH study were presented during a late-breaking oral abstract session at The Liver Meeting.In their study, Miethke, associate professor…

Disparities in transplant access drive mortality in low, middle-income countries

WASHINGTON — Patients with cirrhosis in low- or middle-income countries had an increased risk for inpatient and 30-day mortality, likely due to disparities in transplant access, according to research presented at The Liver Meeting.“Chronic liver disease and cirrhosis are major causes of morbidity and mortality worldwide. We know the differences in etiologies of the disease,…

Disparities in transplant access drive mortality in low, middle-income countries

WASHINGTON — Patients with cirrhosis in low- or middle-income countries had an increased risk for inpatient and 30-day mortality, likely due to disparities in transplant access, according to research presented at The Liver Meeting.“Chronic liver disease and cirrhosis are major causes of morbidity and mortality worldwide. We know the differences in etiologies of the disease,…

Antiviral activity of VIR-2218 boosted by immunomodulators in treatment of chronic HBV

WASHINGTON — Pegylated interferon alpha potentiated the antiviral activity of VIR-2218 in a small subset of noncirrhotic patients with chronic hepatitis B, according to preliminary data presented at The Liver Meeting.“VIR-2218 is a GalNAc-conjugated siRNA shown to reduce hepatitis B surface antigen in patients with chronic hepatitis B infection, and pegylated interferon is an approved…